Key facts
- STATE STREET CORP filed SCHEDULE 13G for SYNDAX PHARMACEUTICALS INC COMMON STOCK (SNDX).
- Disclosed ownership: 5.3%.
- Date of event: 31 Dec 2025.
STATE STREET CORP - 31 Dec 2025 SCHEDULE 13G Report for SYNDAX PHARMACEUTICALS INC COMMON STOCK (SNDX)
- Filing manager
- STATE STREET CORP
- Reporting owner
- STATE STREET CORPORATION
- Beneficially owned shares
- 4,596,552 shares
- Class ownership
- 5.3%
- Symbol
- SNDX
- Shares outstanding
- 86,727,396 shares
- Form type
- SCHEDULE 13G
- Accepted by SEC
- 09 Feb 2026, 08:08:38 UTC
- Event date
- 31 Dec 2025
- SEC filing
- View on sec.gov
Ownership signal
1 fact
Subject security
2 facts
SEC evidence
4 facts
Key filing fact
STATE STREET CORP disclosed 5.3% ownership in SYNDAX PHARMACEUTICALS INC COMMON STOCK (SNDX) on 31 Dec 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 09 Feb 2026, 08:08.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| STATE STREET CORPORATION | 5.3% | 4,596,552 | 0 | 4,341,322 | ELIZABETH SCHAEFER | SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER |
CIK / CUSIP context first